Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to Sell at StockNews.com

StockNews.com cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a hold rating to a sell rating in a research note released on Thursday.

Corvus Pharmaceuticals Trading Up 0.8 %

CRVS stock opened at $4.03 on Thursday. The company has a market capitalization of $252.08 million, a P/E ratio of -7.75 and a beta of 1.13. The business has a 50 day simple moving average of $3.06 and a 200-day simple moving average of $2.32. Corvus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $4.75.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.05. During the same quarter in the previous year, the company posted ($0.14) earnings per share. Research analysts predict that Corvus Pharmaceuticals will post -0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Towerview LLC raised its stake in shares of Corvus Pharmaceuticals by 4.6% during the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after buying an additional 17,500 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter worth about $44,000. Marshall Wace LLP acquired a new stake in shares of Corvus Pharmaceuticals in the second quarter worth approximately $136,000. Vanguard Group Inc. boosted its holdings in shares of Corvus Pharmaceuticals by 10.6% in the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after purchasing an additional 142,724 shares during the last quarter. Finally, Samlyn Capital LLC increased its stake in Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after acquiring an additional 3,774,658 shares during the last quarter. Institutional investors and hedge funds own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.